Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Accumulated Depreciation (2019 - 2022)

Avidity Biosciences (RNA) has disclosed Accumulated Depreciation for 4 consecutive years, with $2.7 million as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Accumulated Depreciation changed N/A year-over-year to $2.7 million, compared with a TTM value of $2.7 million through Sep 2022, changed N/A, and an annual FY2021 reading of $1.7 million, down 12.43% over the prior year.
  • Accumulated Depreciation was $2.7 million for Q3 2022 at Avidity Biosciences, up from $2.4 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $2.7 million in Q3 2022 and bottomed at $1.6 million in Q4 2019.
  • Average Accumulated Depreciation over 4 years is $2.1 million, with a median of $1.9 million recorded in 2020.
  • The sharpest move saw Accumulated Depreciation dropped 12.43% in 2021, then grew 27.57% in 2022.
  • Year by year, Accumulated Depreciation stood at $1.6 million in 2019, then rose by 20.45% to $2.0 million in 2020, then decreased by 12.43% to $1.7 million in 2021, then soared by 58.05% to $2.7 million in 2022.
  • Business Quant data shows Accumulated Depreciation for RNA at $2.7 million in Q3 2022, $2.4 million in Q2 2022, and $1.7 million in Q4 2021.